OnCall

In this episode, the eleventh of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses drug pricing and shortages. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCall@cencora.com .

In this episode, the tenth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses transparency in the House, competition, and lower costs on drugs and services. Our next episode will feature information on drug pricing and shortages. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCall@...

In this episode, the ninth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses health issues around Medicare physician payment, and PBM reform. Our next episode will feature information on transparency in the House, competition, and lower costs on drugs and services. If you have any questions for our guests or have a topic you would like to...

In this episode, the eighth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses MPFS, Medicare Drug Price Negotiations, PBM reform, and elections. That's all for this episode of OnCall. Our next episode will feature information on politics and policy, and physician payment issues. If you have any questions for our guests or have a topic...

In this episode, the seventh of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses Congress and the fiscal backdrop. Our next episode will feature information on issues regarding MPFS, Medicare Drug Price Negotiations, PBM reform, and elections. If you have any questions for our guests or have a topic you would like to learn more about, email...

In this episode, the sixth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses the new DEA proposed rules on prescribing controlled substances and treatments. Our next episode will feature information on payment updates for Medicare. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCa...

In this episode, the fifth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses the End of the Public Health Emergency and what it means for practices. Our next episode will feature information on the New DEA proposed rules on prescribing controlled substances and treatments. If you have any questions for our guests or have a topic you would...

In this episode, the fourth of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs discusses federal budget and debt negotiations and the implications for Medicare, Medicaid and ACA. Our next episode will feature information on the end of the Public Health Emergency and what it means for practices. If you have any questions for our guests or have a topic...

In this episode, the third of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss the Inflation Reduction Act, PBM reform, and 2023 regulations. Our next episode will feature information on federal budget and debt negotiations and the implications for Medicare, Medicaid and ACA. If you have any questions for our guests or have a top...

In this episode, the second of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss drug coverage, pricing, and payment. Our next episode will feature information on the Inflation Reduction Act, PBM reform, and 2023 regulations. If you have any questions for our guests or have a topic you would like to learn more about, email us at O...

In this episode, the first of our GPO Legislative Updates series, Joel White, President and CEO of Horizon Government Affairs, and Tony Lee discuss three important policy trends impacting physicians: Medicare payments, drugs/biologics, and disparities/SDOH. Our next episode will feature information on drug coverage, pricing, and payments. If you have any questions for our guests or have a topic yo...

In this Amgen sponsored podcast, David R. Braxton, MD, Chief of Service for Molecular Pathology at Hoag Hospital, shares his insights as considerations on operationalizing biomarker testing into clinical practice in NSCLC. He discusses considerations on improving the turnaround time of test results, clinical application of ctDNA testing as well as strategies for documentation of results for ease o...

In this episode, the fifth of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about operationalizing biosimilars into practice and the differences and similarities of this process for biosimilars versus their counterparts. If you have any questions for our guests or have a topic you would like to learn more about, email us at OnCall@cencora...

In this episode, the fourth of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about the role of the payer in relation to biosimilars, the formulary management process and the differences in treatment of biosimilars by Medicaid and Medicare. If you have any questions for our guests or have a topic you would like to learn more about, email u...

In this episode, the third of our biosimilar education series, Neil Udovich spoke with Kathy Oubre, CEO of Pontchartrain Cancer Center, about the FDA approval process for biosimilars, the Biologics Price Competition and Innovation Act and safety issues or adverse effects related to biosimilar use. If you have any questions for today’s guests, or have a topic you would like to hear more about, emai...

In this episode, the second of our biosimilar education series, Kathy Oubre, CEO of Pontchartrain Cancer Center, and Neil Udovich, Vice President of Sales for AmerisourceBergen Specialty GPOs, discuss the history of biosimilars, the reception of them in the medical community and their road ahead. If you have any questions for today’s guests, or have a topic you would like to hear more about, email...

In this episode, the first of our biosimilar education series, Kathy Oubre, CEO of Pontchartrain Cancer Center, and Neil Udovich, Vice President of Sales for AmerisourceBergen Specialty GPOs, discuss what biosimilars are (and aren’t), interchangeability with their reference products, and Kathy’s experience with adopting them into her practice. If you have any questions for today’s guests, or have...

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about biomarker testing in the community oncology setting - from the importance of emerging biomarkers to basket and umbrella trial designs. If you have any questions for today’s guests, or have a topic you would like to hear more about, e...

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about biomarker testing in the community oncology setting - from the advantages and disadvantages of liquid biopsies to the benefits of ordering test panels. If you have any questions for today’s guests, or have a topic you would like to h...

In this podcast series brought to you by Invitae, oncology specialists who routinely integrate genetic information into their patients' treatment, discuss actionable options for implementing genomics-informed, personalized cancer care. In the first installment of this series, Dr. Rakesh Patel, Chief Medical Officer, Digital Health, and Dr. Peter Beitsch, Breast Surgical Oncologist, Past Presi...

In the final episode of our buy and bill series, we discuss reducing financial barriers for your patients and talk to Joe Baffone, CEO of Annexus Health, about the benefit of implementing efficient financial navigation programs within your practice. Visit our website for more information or to become a member and ensure you have access to all of our product discounts and rebates, consulting servic...

In this episode, we talk about the reimbursement aspect of the buy and bill model and the four key issues that could negatively impact the health of your revenue cycle. Click here to get in touch with us for more information on this or variety of other topics related to your specialty practice. If you have any questions for today’s guests, or have a topic you would like to hear more about, email O...

In this episode, a part of our biomarker testing series, we are joined by Dr. Manish Patel, Director of Drug Development for Florida Cancer Specialists, to talk about the basics of biomarker testing – from identifying common testing approaches to comparing DNA and RNA sequencing. If you have any questions for today’s guest or have a topic you would like to learn more about, email us at OnCall@cenc...

In this episode, we discuss the benefits of buy and bill, how to get reimbursed, steps to take for timely payment and the important role patient assistance plays to protect the practice from financial risk and protect your patients from financial toxicity. Click here to get in touch with us for more information on this or variety of other topics related to your specialty practice. If you have any...

This is the first episode in our series covering buy and bill. As more drugs that utilize this payment model enter the market, we want to make sure you have the information needed for proper payment and reimbursement. This type of education is just one essential benefit of a free GPO membership. In this episode, we cover the many advantages of a GPO membership and begin our overview of the buy and...